FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)

On January 20, Leonid Timashev of RBC Capital maintained an Outperform standing connected Legend Biotech (NASDAQ:LEGN) and acceptable a $66 terms target. The expert shed airy connected the FDA’s draught guidance that supports the usage of Minimal Residual Disease (MRD) negativity and implicit effect complaint to expedite support endpoints successful aggregate myeloma. This appears favorable for Legend Biotech (LEGN), arsenic it supports the company’s proceedings plan and enhances near-term visibility for the CARTITUDE-6 survey successful the archetypal attraction setting.

Tonhom1009/Shutterstock.com

On January 20, Raymond James besides reaffirmed its Outperform standing connected Legend Biotech (NASDAQ:LEGN) with an $86 terms target. The steadfast besides attributed its bullish stance to the FDA’s projected guidance that backs the usage of Minimal Residual Disease (MRD) and implicit effect complaint for accelerated approvals successful aggregate myeloma. Moreover, the steadfast believes specified endpoints are invaluable successful little assertive forms of the disease, wherever endurance outcomes often necessitate astatine slightest 4 to 5 years to amusement meaningful changes.

Legend Biotech (NASDAQ:LEGN) is simply a commercial-stage biopharmaceutical institution that develops innovative therapies. Being an end-to-end compartment therapy company, they absorption connected medicine for superior diseases specified arsenic hematologic malignancies and coagulated tumors.

While we admit the imaginable of LEGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.